Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 58 articles:
HTML format
Text format



Single Articles


    May 2018
  1. AL HABYAN S, Kalos C, Szymborski J, McCaffrey L, et al
    Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.
    Oncogene. 2018 May 23. pii: 10.1038/s41388-018-0317.
    PubMed     Text format     Abstract available


  2. GABBASOV R, Xiao F, Howe CG, Bickel LE, et al
    NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.
    Oncogene. 2018 May 18. pii: 10.1038/s41388-018-0296.
    PubMed     Text format     Abstract available


  3. RADA M, Nallanthighal S, Cha J, Ryan K, et al
    Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Oncogene. 2018 May 17. pii: 10.1038/s41388-018-0297.
    PubMed     Text format     Abstract available


    April 2018
  4. DORAYAPPAN KDP, Wanner R, Wallbillich JJ, Saini U, et al
    Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.
    Oncogene. 2018 Apr 11. pii: 10.1038/s41388-018-0189.
    PubMed     Text format     Abstract available


    February 2018
  5. LADANYI A, Mukherjee A, Kenny HA, Johnson A, et al
    Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
    Oncogene. 2018 Feb 5. pii: 10.1038/s41388-017-0093.
    PubMed     Text format     Abstract available


    January 2018
  6. AKHTER MZ, Sharawat SK, Kumar V, Kochat V, et al
    Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0106.
    PubMed     Text format     Abstract available


  7. GRITHER WR, Divine LM, Meller EH, Wilke DJ, et al
    TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0043.
    PubMed     Text format     Abstract available


    October 2017
  8. WANG J, Kho DH, Zhou JY, Davis RJ, et al
    MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
    Oncogene. 2017;36:5939-5947.
    PubMed     Text format     Abstract available


    September 2017
  9. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  10. GUO H, Zhu Q, Yu X, Merugu SB, et al
    Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.
    Oncogene. 2017;36:5098-5109.
    PubMed     Text format     Abstract available


    August 2017
  11. SOMASAGARA RR, Spencer SM, Tripathi K, Clark DW, et al
    RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
    Oncogene. 2017 Aug 14. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    June 2017
  12. TO SKY, Mak ASC, Eva Fung YM, Che CM, et al
    beta-catenin downregulates Dicer to promote ovarian cancer metastasis.
    Oncogene. 2017 Jun 26. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  13. KLYMENKO Y, Kim O, Loughran E, Yang J, et al
    Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    May 2017
  14. ZHAO J, Wang Y, Mu C, Xu Y, et al
    MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
    Oncogene. 2017 May 1. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  15. NIU N, Mercado-Uribe I, Liu J
    Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    March 2017
  16. SHANG Y, He J, Wang Y, Feng Q, et al
    CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  17. BASULI D, Tesfay L, Deng Z, Paul B, et al
    Iron addiction: a novel therapeutic target in ovarian cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  18. COMISSO E, Scarola M, Rosso M, Piazza S, et al
    OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  19. GUPTA R, Yang Q, Dogra SK, Wajapeyee N, et al
    Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    February 2017
  20. HWANG MH, Cho KH, Jeong KJ, Park YY, et al
    RCP induces Slug expression and cancer cell invasion by stabilizing beta1 integrin.
    Oncogene. 2017;36:1102-1111.
    PubMed     Text format     Abstract available


  21. HARJES U, Bridges E, Gharpure KM, Roxanis I, et al
    Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.
    Oncogene. 2017;36:912-921.
    PubMed     Text format     Abstract available


  22. LAU TS, Chan LK, Wong EC, Hui CW, et al
    A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFalpha-TGFalpha-EGFR.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    January 2017
  23. ZHAO L, Ji G, Le X, Luo Z, et al
    An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.
    Oncogene. 2017 Jan 23. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    December 2016
  24. MODI DA, Tagare RD, Karthikeyan S, Russo A, et al
    PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  25. GURLER MAIN H, Xie J, Muralidhar GG, Elfituri O, et al
    Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma.
    Oncogene. 2016 Dec 12. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    November 2016
  26. WILSON C, Qiu L, Hong Y, Karnik T, et al
    The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  27. DIMITROVA N, Nagaraj AB, Razi A, Singh S, et al
    InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer.
    Oncogene. 2016 Nov 7. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    October 2016
  28. MATSUURA K, Huang NJ, Cocce K, Zhang L, et al
    Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  29. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  30. WITT AE, Lee CW, Lee TI, Azzam DJ, et al
    Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    September 2016
  31. FANG D, Chen H, Zhu JY, Wang W, et al
    Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2016 Sep 12. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  32. CHAN DW, Hui WW, Wang JJ, Yung MM, et al
    DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-beta/SMAD4 signaling.
    Oncogene. 2016 Sep 5. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  33. WANG Y, Justilien V, Brennan KI, Jamieson L, et al
    PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.
    Oncogene. 2016 Jun 20. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  34. SAINI U, Naidu S, ElNaggar AC, Bid HK, et al
    Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.
    Oncogene. 2016 Jun 13. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  35. DE CIAN MC, Pauper E, Bandiera R, Vidal VP, et al
    Amplification of R-spondin1 signaling induces granulosa cell fate defects and cancers in mouse adult ovary.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    April 2016
  36. OZES AR, Miller DF, Ozes ON, Fang F, et al
    NF-kappaB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.
    Oncogene. 2016 Apr 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    March 2016
  37. ZHANG L, Ma T, Brozick J, Babalola K, et al
    Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
    Oncogene. 2016 Mar 14. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    February 2016
  38. SEVIOUR EG, Sehgal V, Lu Y, Luo Z, et al
    Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.
    Oncogene. 2016;35:801.
    PubMed     Text format    


    January 2016
  39. PARK CS, Kim TK, Kim HG, Kim YJ, et al
    Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis.
    Oncogene. 2016 Jan 25. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  40. YAGI H, Asanoma K, Ohgami T, Ichinoe A, et al
    GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.
    Oncogene. 2016 Jan 25. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  41. GEORGE SH, Milea A, Sowamber R, Chehade R, et al
    Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis.
    Oncogene. 2016;35:59-68.
    PubMed     Text format     Abstract available


    December 2015
  42. DUCKWORTH C, Zhang L, Carroll SL, Ethier SP, et al
    Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.
    Oncogene. 2015 Dec 14. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    November 2015
  43. SHIGETA S, Toyoshima M, Kitatani K, Ishibashi M, et al
    Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer.
    Oncogene. 2015 Nov 9. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    October 2015
  44. PANGON L, Ng I, Giry-Laterriere M, Currey N, et al
    JRK is a positive regulator of beta-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer.
    Oncogene. 2015 Oct 12. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    September 2015
  45. CHEN J, Bai M, Ning C, Xie B, et al
    Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1alpha/cyclin D1 pathway.
    Oncogene. 2015 Sep 14. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  46. KITATANI K, Usui T, Sriraman SK, Toyoshima M, et al
    Ceramide limits phosphatidylinositol-3-kinase C2beta-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.
    Oncogene. 2015 Sep 14. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    August 2015
  47. NAGARAJA AS, Dorniak PL, Sadaoui NC, Kang Y, et al
    Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.
    Oncogene. 2015 Aug 10. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  48. PRUDNIKOVA TY, Villamar-Cruz O, Rawat SJ, Cai KQ, et al
    Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.
    Oncogene. 2015 Aug 10. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    July 2015
  49. TIMSAH Z, Ahmed Z, Ivan C, Berrout J, et al
    Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.
    Oncogene. 2015 Jul 27. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  50. SHINDERMAN-MAMAN E, Cohen K, Weingarten C, Nabriski D, et al
    The thyroid hormone-alphavbeta3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation.
    Oncogene. 2015 Jul 13. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    June 2015
  51. YAN L, Zhou J, Gao Y, Ghazal S, et al
    Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation.
    Oncogene. 2015;34:3076-84.
    PubMed     Text format     Abstract available


  52. GOLMARD L, Delnatte C, Lauge A, Moncoutier V, et al
    Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.
    Oncogene. 2015 Jun 1. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    April 2015
  53. CARVALHO S, Lindzen M, Lauriola M, Shirazi N, et al
    An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.
    Oncogene. 2015 Apr 27. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  54. HE Y, Wu AC, Harrington BS, Davies CM, et al
    Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
    Oncogene. 2015 Apr 20. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  55. TUTHILL MH, Montinaro A, Zinngrebe J, Prieske K, et al
    TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
    Oncogene. 2015;34:2138-44.
    PubMed     Text format     Abstract available


    March 2015
  56. ADAMS MN, Harrington BS, He Y, Davies CM, et al
    EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.
    Oncogene. 2015;34:1375-83.
    PubMed     Text format     Abstract available


    February 2015
  57. LIN YG, Shen J, Yoo E, Liu R, et al
    Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis.
    Oncogene. 2015 Feb 16. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    August 2014
  58. PAUL BT, Blanchard Z, Ridgway M, ElShamy WM, et al
    BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
    Oncogene. 2014 Aug 18. doi: 10.1038/onc.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: